A study conducted with Japanese patients with T2DM found that treatment with an SGLT2 inhibitor (luseogliflozin or dapagliflozin) was associated with an overall increase in the prevalence of balance-regulating bacteria, including SCFA-producing bacteria [254]. Here, SLC5A2 is linked to type 2 diabetes mellitus.